Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 2/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | EED | O75530 | 3/20 | 0.33 |
| ▸ | RBBP4 | Q09028 | 3/20 | 0.33 |
| ▸ | SUZ12 | Q15022 | 3/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26083492 | 1.00 | ATR (0.34) | ATRPDK4DGAT2EEDRBBP4 | |
| SCHEMBL24469114 | 0.91 | ATR (0.35) | ATRPDK4DGAT2EEDRBBP4 | |
| SCHEMBL26083494 | 0.88 | ATR (0.33) | ATRPDK4EEDRBBP4SUZ12 | |
| SCHEMBL24469188 | 0.80 | ATR (0.34) | ATRPDK4EEDRBBP4SUZ12 | |
| SCHEMBL30493660 | 0.79 | — | — | |
| SCHEMBL30368541 | 0.75 | — | — | |
| SCHEMBL26083491 | 0.75 | — | — | |
| SCHEMBL30493735 | 0.71 | — | — | |
| SCHEMBL30368338 | 0.69 | MAPT (0.32) | — | |
| SCHEMBL26083489 | 0.69 | MAPT (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320212-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORP (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4620469-A2 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4175719-B1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORP (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12187725-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240150354-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4175719-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20220169649-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320212-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | ATR 3246/4885PDK4 2165/4885DGAT2 3482/4885 |
| US-20240150354-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | ATR 3246/4885PDK4 2165/4885DGAT2 3482/4885 |
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | ATR 3246/4885PDK4 2165/4885DGAT2 3482/4885 |
| US-12187725-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | ATR 3246/4885PDK4 2165/4885DGAT2 3482/4885 |
| US-20220169649-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | ATR 3246/4885PDK4 2165/4885DGAT2 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.